You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EGFR C797X

Showing 1 - 25 of 2,675
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Tumor, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-701, osimertinib, carboplatin)

Recruiting
  • Lung Neoplasm
  • +26 more
  • Boston, Massachusetts
  • +6 more
Jun 23, 2022

EGFR Mutant Advanced NSCLC Trial (JIN-A02)

Not yet recruiting
  • EGFR Mutant Advanced Non-small Cell Lung Cancer
  • (no location specified)
Jul 8, 2022

Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Worldwide (BLU-945, osimertinib)

Recruiting
  • Lung Neoplasms
  • +23 more
  • La Jolla, California
  • +35 more
Oct 6, 2022

BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Tumor Trial in Houston (biological, drug, other)

Active, not recruiting
  • BRAF NP_004324.2:p.V600X
  • +6 more
  • Cetuximab
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Locally Advanced or Metastatic NSCLC Trial in Shanghai (WJ13404 tablets)

Recruiting
  • Locally Advanced or Metastatic NSCLC
  • WJ13404 tablets
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Dec 14, 2022

NSCLC Trial in Worldwide (Osimertinib, Savolitinib, Gefitinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • Duarte, California
  • +52 more
Jan 19, 2023

NSCLC Trial (Furmonertinib)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • (no location specified)
Aug 10, 2023

EGFR Mutant Advanced NSCLC Trial (BBT-207)

Not yet recruiting
  • EGFR Mutant Advanced Non-Small Cell Lung Cancer
  • (no location specified)
Jun 16, 2023

NSCLC Trial (TAS3351 oral administration)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • TAS3351 oral administration
  • (no location specified)
Mar 8, 2023

Carcinoma, Non-Small-Cell Lung Trial in Worldwide (Savolitinib, Osimertinib, Pemetrexed)

Not yet recruiting
  • Carcinoma
  • Non-Small-Cell Lung
  • Orange City, Florida
  • +78 more
Jul 20, 2022

Lung Cancer Trial in Worldwide (T790M+ Testing, Baseline Visit Blood & Urine Testing, Baseline ECG)

Completed
Has Results
  • Lung Cancer
  • T790M+ Testing
  • +4 more
  • Buenos Aires, Argentina
  • +200 more
Nov 10, 2021

NSCLC, EGFR Gene Mutation, EGF-R Positive NSCLC Trial in Jerusalem (Stereotactic surgery)

Recruiting
  • NSCLC
  • +4 more
  • Stereotactic surgery
  • Jerusalem, Israel
    Hadassah Ein Kerem Medical Center
Aug 30, 2021

NSCLC Trial in Singapore (Afatinib 40 MG)

Not yet recruiting
  • NSCLC
  • Afatinib 40 MG
  • Singapore, Singapore
    National University Hospital
Sep 25, 2023

Lung Cancer, TKI Resistance, EGFR Sensitive Mutation Trial (Anlotinib, Penpulimab)

Not yet recruiting
  • Lung Cancer
  • +4 more
  • (no location specified)
Sep 15, 2023

Advanced or Metastatic NSCLC Trial in Guangzhou (HS-10375)

Recruiting
  • Advanced or Metastatic NSCLC
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jun 27, 2022

Non Small Cell Lung Cancer Trial in Seoul (Neoadjuvant lazertinib)

Recruiting
  • Non Small Cell Lung Cancer
  • Neoadjuvant lazertinib
  • Seoul, Korea, Republic of
    Konkuk University Medical Center
Jul 20, 2022

Non-squamous NSCLC Trial in Guangzhou (FSRT combined with Bevacizumab)

Active, not recruiting
  • Non-squamous Non-small Cell Lung Cancer
  • FSRT combined with Bevacizumab
  • Guangzhou, China
    Sun Yat-sen University
Nov 25, 2022

Advanced or Metastatic Colorectal Cancer Trial in Worldwide (Amivantamab, Fluorouracil, Leucovorin)

Recruiting
  • Advanced or Metastatic Colorectal Cancer
  • Birmingham, Alabama
  • +85 more
Jan 27, 2023

Diagnostic Value of Serum Cathepsin S and Chromogranin A in DKD

Not yet recruiting
  • Diabetic Kidney Disease
  • cathepsin S and chromogranin A
  • (no location specified)
Oct 5, 2023

NSCLC Trial (QLH11811)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
Sep 22, 2022

A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib

Recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • +4 more
    • Guangzhou, Guangdong, China
      Cancer Center, Sun Yat-sen University
    Oct 25, 2022

    Non-squamous NSCLC Trial (biological, drug, dietary supplement)

    Not yet recruiting
    • Non-squamous NSCLC
    • Pembrolizumab
    • +7 more
    • (no location specified)
    Feb 20, 2023

    Chronic Kidney Disease Trial in Worldwide (Zibotentan, Dapagliflozin, Placebo)

    Recruiting
    • Chronic Kidney Disease
    • Huntsville, Alabama
    • +251 more
    Dec 22, 2022

    Treatment, Treatment Side Effects Trial in China (YK-029A)

    Recruiting
    • Treatment
    • Treatment Side Effects
    • Hefei, Anhui, China
    • +34 more
    Mar 15, 2023

    Excision Repair Cross Complementation Group 1 in Laryngeal

    Not yet recruiting
    • Laryngeal Squamous Cell Carcinoma
    • Immunohistochemistry
    • (no location specified)
    Apr 15, 2023